COST EFFECTIVENESS ANALYSIS;
DRUG EFFICACY;
DRUG MARKETING;
DRUG SAFETY;
EDITORIAL;
FUNDING;
HEALTH PROGRAM;
HUMAN;
IMMUNOGENICITY;
MENINGOCOCCOSIS;
PATIENT ADVOCACY;
PRIORITY JOURNAL;
QUALITY OF LIFE;
UNITED KINGDOM;
Joint Committee on Vaccination and Immunisation, July, 2013. Department of Health
Joint Committee on Vaccination and Immunisation. JCVI interim position statement on the use of Bexsero meningococcal B vaccine in the UK, July, 2013. Department of Health, 2013. www.gov.uk/government/publications/jcvi-interim- position-statement-on-the-useof- bexsero-meningococcal-b-vaccine-in-the-uk.
Joint Committee on Vaccination and Immunisation, February
Joint Committee on Vaccination and Immunisation. Minute of the meeting on 11th/12th February 2014. www.gov.uk/government/policy-advisory-groups/joint- committee-onvaccination- and-immunisation.
News Agencies. Meningitis B vaccine set to be made available for babies in Government adviser U-turn. Daily Telegraph 2014. www.telegraph.co.uk/health/ children-shealth/ 10713516/Meningitis-B-vaccine-set-to-be-made-available-for- babies-in-Governmentadviser- U-turn.html.
Health Protection Agency. Invasive meningococcal infections laboratory reports, England and Wales by capsular group and epidemiological year, 1998-2012. 2012. www.hpa.org. uk/webc/HPAwebFile/HPAweb-C/1317136087786.
Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales
published online 25 Feb
Chamberlain C, Collin SM, Stephens P, Donovan J, Bahl A, Hollingworth W. Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales. Br J Cancer 2014; published online 25 Feb.